<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732234</url>
  </required_header>
  <id_info>
    <org_study_id>IORG0003381-AP2006-50103</org_study_id>
    <nct_id>NCT04732234</nct_id>
  </id_info>
  <brief_title>Pre-emptive US Guided Superior Hypogastric Plexus Block in Pelvic Cancer Surgeries : a Randomized Double-Blinded Study</brief_title>
  <official_title>Pre-emptive Ultrasound Guided Superior Hypogastric Plexus Block in Pelvic Cancer Surgeries : a Randomized Double-Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The superior hypogastric plexus (SHP) is a retroperitoneal structure with a predominance of&#xD;
      afferent sympathetic nerve fibers. The perception of central pelvic pain is thought mainly to&#xD;
      involve transmission through this plexus. Therefore, blocking or of SHP has been used to&#xD;
      treat pelvic pain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ultrasound guided superior hypogastric plexus block there is 2 equal groups:&#xD;
&#xD;
      Group S (SHPB group 18 patients) ultrasound guided SHPB is done after induction of balanced&#xD;
      general anesthesia (fentanyl, propofol and rocuronium) using 20 ml Bupivacaine 0.5% before&#xD;
      skin incision, Group C (Control group 18 patients) in which same technique will be done but&#xD;
      using normal saline 0.9% instead of bupivacaine. Patients of both groups will receive patient&#xD;
      controlled analgesia using morphine with continous background infusion of morphine 1.5 mg/h&#xD;
      with adding granisterone 2mg/60 ml and ability to give bolus of 0.5 mg morphine on demand.&#xD;
&#xD;
      â€¢ Dosing and administration; Group S (SHPB group 18 ultrasound guided SHPB ) using 20 ml&#xD;
      Bupivacaine 0.5% before skin incision.&#xD;
&#xD;
      Group C (Control group 18 patients) in which same technique will be done but using normal&#xD;
      saline 0.9%&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group S (SHPB group 18 ultrasound guided SHPB ) using 20 ml Bupivacaine 0.5% before skin incision.&#xD;
Group C (Control group 18 patients) in which same technique will be done but using normal saline 0.9%</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomization is done using computer generated sequence. Concealment will be achieved by opaque envelope.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>morphine consumption</measure>
    <time_frame>baseline till 24 hours postoperative</time_frame>
    <description>Total 24 hours morphine consumption in milligrams</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale (VAS)</measure>
    <time_frame>Visual analogue scale (VAS) at baseline till 24 hours postoperative</time_frame>
    <description>scale in which 0 is least pain and 10 is sever pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Analgesia</condition>
  <arm_group>
    <arm_group_label>( Group A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ultrasound guided superior hypogastric plexus block using 20 ml Bupivacaine 0.5% before skin incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Group B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ultrasound guided superior hypogastric plexus block using 20 ml normal saline 0.9% instead of bupivacaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Superior Hypogastric Plexus Block</intervention_name>
    <description>Pre operative ultrasound guided superior hypogastric plexus block in pelvic surgeries using a curvilinear probe below umbalicus with needle in plane technique to reach the plexus in front of L5 vertebra</description>
    <arm_group_label>( Group A)</arm_group_label>
    <arm_group_label>(Group B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA II,III.&#xD;
&#xD;
          -  Patients undergoing pelvic surgeries.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients refusal,&#xD;
&#xD;
          -  Coagulopathy,&#xD;
&#xD;
          -  Infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed abdel wadod, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesia &amp; pain management Dept, National Cancer Institute-Cairo - Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nataional Cancer Instituite</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 25, 2020</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Mohammed Abdelfattah Abdelwadod</investigator_full_name>
    <investigator_title>Mohammed Abdelfattah Abdelwadod</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

